Related Experiment Videos
[Effect of cefotaxime on hemostasis]
T Kamiya1, H Saito, N Sakuragawa
1First Department of Internal Medicine, School of Medicine, Nagoya University.
The Japanese Journal of Antibiotics
|July 1, 1987
Summary
Cefotaxime (CTX) administration rarely causes abnormal hemostatic tests in patients. Abnormal coagulation results were observed in 1.2% of patients, primarily those with pre-existing liver damage and poor nutrition, without clinical bleeding.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Context:
- A study involving 1,043 adult patients treated with cefotaxime (CTX) for infections across 368 Japanese hospitals.
- Patients had diverse underlying conditions, predominantly nonhematological disorders (1,012) and fewer hematological diseases (31).
Purpose:
- To investigate the incidence and characteristics of hemostatic abnormalities associated with cefotaxime administration.
- To determine the relationship between patient condition and the occurrence of abnormal blood coagulation tests.
Summary:
- Thirteen patients (1.2%) exhibited abnormal blood coagulation tests post-cefotaxime treatment.
- All affected patients had poor dietary intake and evidence of liver damage, either pre-existing or during treatment.
- No clinical bleeding symptoms were observed in any patients with abnormal coagulation test results.
Impact:
- The findings suggest a low incidence of cefotaxime-induced hemostatic test abnormalities.
- Patient-specific factors, particularly liver function and nutritional status, appear to be significant determinants of these laboratory findings.